OVERVIEW

Community Practice Connections™: Medical Crossfire®: A New Dawn of T-Cell–Engaging Immunotherapy: Improving Outcomes for Patients with Acute Lymphoblastic Leukemia (ALL) is organized by Physicians' Education Resource, LLC (PER).

Release Date: November 27, 2019
Expiration Date: November 27, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
This activity will feature reviews of the latest data covering advances in treatment for acute lymphoblastic leukemia (ALL), followed by case presentations and expert discussion to place emerging treatment options into context. The emergence of T-cell engaging therapies to treat lymphomas and leukemias have created new opportunities in the treatment of relapsed/refractory ALL or ALL in remission with measurable residual disease (MRD). Bispecific T-cell engagers can redirect T-cells to exert cytotoxic activity against tumor cells and have demonstrated efficacy in B-cell ALL (B-ALL). However, identifying which patients and at which point in therapy these new agents should be used can be challenging given rapidly emerging data and advances in strategies to monitor response to lines of therapy, such as MRD.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Gain an understanding of the latest data regarding the use of T-cell engaging therapies in the treatment of ALL.
• Hear expert perspective on how and when to apply the latest advances in treatment for ALL.
• Utilize real-world case studies to challenge your treatment decision-making in light of emerging options and novel data in ALL.

Benefits of Participating:
• Gain an understanding of the latest data regarding the use of T-cell engaging therapies in the treatment of ALL.
• Hear expert perspective on how and when to apply the latest advances in treatment for ALL.
• Utilize real-world case studies to challenge your treatment decision-making in light of emerging options and novel data in ALL.